title: Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis.
abstract: OBJECTIVE
  To assess the efficacy and tolerability of adjunctive pharmacotherapy for smoking cessation in adults with serious mental illness (SMI) by means of a systematic review and network meta-analysis.
  
  
  METHODS
  We searched Embase, Medline, PsychINFO and the Cochrane Central Register of Controlled Trials from database inception to 1 December 2014 for randomized controlled trials (RCTs) published in English. We included all studies of smokers with SMI (including schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder and depressive psychoses) who were motivated to quit smoking. Pharmacotherapies included nicotine replacement therapy (NRT), bupropion and varenicline delivered as monotherapy or in combination compared with each other or placebo. The efficacy outcome was self-reported sustained smoking cessation, verified biochemically at the longest reported time-point. The tolerability outcome was number of patients discontinuing the trial due to any adverse event.
  
  
  RESULTS
  Seventeen study reports were included, which represented 14 individual RCTs. No trials were found in patients with depressive psychoses, delusional disorder or that compared NRT monotherapy with placebo. A total of 356 and 423 participants were included in the efficacy and tolerability analyses, respectively. From the network meta-analysis, both bupropion and varenicline were more effective than placebo [odds ratio (OR) = 4.51, 95% credible interval (CrI) = 1.45-14.04 and OR = 5.17, 95% CrI = 1.78-15.06, respectively]. Data were insensitive to an assessment of varenicline versus bupropion (OR = 1.15, 95% CrI = 0.24-5.45). There were no significant differences in tolerability. All outcomes were rated by GRADE criteria as very low quality.
  
  
  CONCLUSIONS
  The limited evidence available to date suggests that bupropion and varenicline are effective and tolerable for smoking cessation in adults with serious mental illnesses.
authors.affiliation: Academic Clinical Fellow in Psychiatry, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
authors.forename: Emmert
authors.initials: E
authors.lastname: Roberts
authors.affiliation: William Cox Family Associate Professor of Psychiatry in the Field of Addiction Medicine, Harvard Medical School, Boston, MA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Eden Evins
authors.affiliation: Professor of Tobacco Addiction, National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
authors.forename: Ann
authors.initials: A
authors.lastname: McNeill
authors.affiliation: Senior Post-Doctorate Researcher in Tobacco Addiction, National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
authors.forename: Debbie
authors.initials: D
authors.lastname: Robson
mesh_terms: D016642:Bupropion / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000150:complications*; D018722:Nicotinic Agonists / Q000627:therapeutic use; D016540:Smoking Cessation / Q000379:methods*; D061485:Tobacco Use Cessation Devices; D014029:Tobacco Use Disorder / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome; D000068580:Varenicline / Q000627:therapeutic use
chemical_list: D018722:Nicotinic Agonists; D016642:Bupropion; D000068580:Varenicline
keywords: Bupropion; NRT; serious mental illness; smoking cessation; tobacco; varenicline